EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence

Naveed Sattar iD, Luis-Emilio García-Pérez iD, Angel Rodríguez iD, Richa Kapoor iD, Adam Stefanski, Emily R Hankosky iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16549 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Naveed Sattar und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Obesity, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Tirzepatide. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Globally, cardiovascular diseases (CVDs) account for around one‐third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon‐like peptide‐1 (GLP‐1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all‐cause mortality. Tirzepatide is a once‐weekly, dual glucose‐dependent insulinotropic polypeptide (GIP) and GLP‐1 receptor agonist that has demonstrated dose‐dependent efficacy in people with obesity, T2D or both, in terms of glycaemic control and bodyweight reduction in clinical trials. This narrative review summarizes the current evidence regarding the effects of tirzepatide treatment on cardiometabolic parameters, including lipid profile, blood pressure and markers of renal function. Additionally, it summarizes the reported impact of tirzepatide treatment on other relevant parameters, such as body composition, liver fat, progression to T2D among individuals with prediabetes, and incidence of heart failure events. Considering the changing landscape of clinical trial evidence of tirzepatide's effects, this review aims to compile the available evidence, which suggests a promising outlook for the cardiometabolic benefits of tirzepatide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityDiabetes Mellitus, Type 2Cardiovascular DiseasesTirzepatideHypoglycemic AgentsGastric Inhibitory PolypeptideHumansGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

cardiometabolic factorscardiovascular diseaseobesitytirzepatide

Substanzen

TirzepatideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Naveed Sattar, Luis-Emilio García-Pérez, Angel Rodríguez, Richa Kapoor, Emily R Hankosky

Förderung

  • Eli Lilly and Company

Zitieren

APA

Sattar, N., García-Pérez, L. E., Rodríguez, A., Kapoor, R., Stefanski, A., & Hankosky, E. R. (2025). Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16549

Vancouver

Sattar N, García-Pérez LE, Rodríguez A, Kapoor R, Stefanski A, Hankosky ER. Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16549

BibTeX
@article{Sattar2025,
  author = {Sattar, Naveed and García-Pérez, Luis-Emilio and Rodríguez, Angel and Kapoor, Richa and Stefanski, Adam and Hankosky, Emily R},
  title = {Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16549}
}
Kostenlos starten →